Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- OncoTree
- LUNG
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,127 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05387109 | Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer(pcwaintrl) | unknown | Phase 4 | 41 | Tang-Du HospitalOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT05085054 | Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 0 |
| May 20, 2022 |
| clinicaltrials |
| NCT05319886 | Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients(AP) | unknown | — | 40 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT05377788 | Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer | unknown | — | 900 | Samsung Medical CenterOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05380999 | The Red Blood Cells Based Blood Test for Lung Cancer EARLY Detection | unknown | — | 852 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT05380271 | Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC | unknown | Phase 2 | 60 | Gang WuOTHER | 0 | May 18, 2022 | clinicaltrials |
| NCT04052412 | Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer | unknown | Phase 1 | 2 | University of TennesseeOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT03606239 | NSCLC Isotoxic Hypofractionated Chemoradiotherapy(IHRC) | unknown | N/A | 30 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03606291 | NSCLC Isotoxic Hypofractionated Radiotherapy(IHR) | unknown | N/A | 30 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04009915 | VATS VS. Open Thoracic Surgery for Stage II - III Lung Cancer(VOLCANO) | unknown | Phase 3 | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT01585545 | Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers | unknown | — | 500 | Samsung Medical CenterOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05360979 | A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC | unknown | Phase 2 | 42 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05358041 | Cone Beam CT Guided Robotic Navigational Bronchoscopy(CBCTRNB) | unknown | — | 200 | Columbus Regional HealthOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04878107 | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy(SABRE) | unknown | Phase 2 | 88 | Wuhan UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT03563482 | Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy. | unknown | N/A | 500 | Istituto Clinico HumanitasOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05351320 | WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC | unknown | Phase 2 | 40 | Jinming YuOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT03997799 | Comparison of Two Techniques of Uniportal VATS Lobectomies for Clinical Stage I Non-Small Cell Lung Cancer | unknown | N/A | 20 | Pulmonary Hospital ZakopaneOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04743752 | Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer | unknown | — | 200 | Peking University First HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346952 | A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | unknown | Phase 3 | 390 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03679936 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer | unknown | — | 120 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04948047 | Breath Combined With CT for Diagnoses of Pulmonary Nodules | unknown | — | 900 | Peking University People's HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05332171 | Examination Of Exercise Adherence İn Lung Cancer Patients Given Calisthenic Exercise | unknown | N/A | 30 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT04759651 | Sleep Disorders in Patients With Suspected Lung Cancer Before and After Thoracic Surgery | unknown | — | 1,200 | Koç UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05319145 | PeRsonalizing the Approach to the Oncologic Frail Individual Through Tailored Assessment and Intervention (PROFIT Study)(PROFIT) | unknown | N/A | 268 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 2 | Apr 13, 2022 | clinicaltrials |
| NCT05320458 | Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer | unknown | N/A | 11 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02817945 | Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | unknown | Phase 2 | 192 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT01470716 | Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations | unknown | Phase 2 | 26 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03612154 | Study of Lorlatinib in ROS1 Rearranged NSCLC | unknown | Phase 2 | 35 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | unknown | Phase 2 | 22 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04040361 | Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | unknown | Phase 2 | 24 | Masahiro TsuboiOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05314296 | Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy(TRUST) | unknown | — | 70 | N.N. Blokhin National Medical Research Center of OncologyOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05306847 | Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | unknown | Phase 2 | 93 | Peking Union Medical College HospitalOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT04325763 | A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 315 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05299385 | The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.) | unknown | Phase 3 | 100 | Lifesemantics Corp.INDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05299255 | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC(ADIVO Lung) | unknown | Phase 1 / Phase 2 | 53 | National University Hospital, SingaporeOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT05296369 | Folic Acid Interferes With Radiation Esophagitis | unknown | N/A | 90 | Guizhou Medical UniversityOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT04828850 | Preoperative Lymph Node Staging With EBUS-TBNA in Clinical N0 Non Small-cell Lung Cancer | unknown | N/A | 50 | European Institute of OncologyOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05287386 | A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05284994 | TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 160 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
Data updated 24 days agoSource updated May 24, 2022source: clinicaltrials